11.1
药学等效性
根据监管标准的定义，药学等效性要求仿制药产品具有相同的剂型，并含有化学性质相同的活性药物成分（API）。此类产品必须符合药典或相关标准中关于效价、含量均匀度、崩解时限和溶出速率等方面的要求。对于改良释放剂型，只要递送的有效药物量与原研制剂保持一致，药物含量允许存在一定差异。然而，相同API的不同盐型…
药物等效物在相似的给药周期内递送相同数量的活性药物成分或API。
当仿制药含有相同剂量的活性药物成分并具有相同的剂型时，其在药学上与原研药等效。
它们必须符合药典规定的效价、含量均匀性、崩解时间和溶出速率标准。
如果递送的药物量与原研产品相同，则允许缓释制剂中的药物含量存在差异。
然而，根据美国食品药品监督管理局（FDA）的定义，相同活性药物成分的不同盐型或前药不被视为药学等效物。
药学等效产品可能含有不同的辅料或允许存在的杂质，在形状、包装、标签和物理特性方面也可能存在差异。
原料药（API）的特性，如粒径、多晶型、纯度、稳定性及立体化学，会影响药品的药学等效性。
药物递送系统、剂型的物理特性、无菌性、过量以及生产工艺也会影响其等效性。
View the full transcript and gain access to JoVE Core videos
Q1: What makes a generic drug pharmaceutically equivalent to a brand-name drug?
A generic drug is pharmaceutically equivalent when it contains the same amount of active pharmaceutical ingredient in the same dosage form as the reference drug. It must meet compendial standards for potency, content uniformity, disintegration time, and dissolution rate. These requirements ensure consistent therapeutic performance across batches.
Q2: Can pharmaceutical equivalents differ in their inactive ingredients?
Yes, pharmaceutically equivalent products may contain different excipients and impurities while maintaining the same active ingredient and dosage form. They can also vary in shape, packaging, and labeling. However, these differences must not affect the drug's bioavailability or therapeutic effectiveness.
Q3: How do particle size and polymorphism affect pharmaceutical equivalence?
Particle size, polymorphism, and other API characteristics like purity and stereochemistry directly influence pharmaceutical equivalence. Different polymorphic forms or particle sizes can alter drug dissolution and absorption rates. These factors must remain consistent with the innovator product to maintain equivalence.
Q4: Are different salt forms of the same API considered pharmaceutical equivalents?
No, different salt forms or prodrugs of the same API do not meet the FDA's definition of pharmaceutical equivalents. Although they contain the same active ingredient, variations in salt form or prodrug structure are considered distinct pharmaceutical entities requiring separate regulatory evaluation.
Q5: What role does the manufacturing process play in pharmaceutical equivalence?
Manufacturing processes, drug delivery systems, sterility, and overage significantly affect pharmaceutical equivalence. The physical attributes of the dosage form, including those influenced by formulation and manufacturing process physical attributes, must align with the innovator product to ensure consistent drug delivery and therapeutic outcomes.
Q6: How are modified-release dosage forms evaluated for pharmaceutical equivalence?
Modified-release dosage forms may have variations in drug content as long as the total delivered drug amount remains identical to the innovator product. This flexibility accommodates different release mechanisms while maintaining therapeutic equivalence and ensuring patients receive consistent drug exposure over the dosing period.
Q7: Why is API stability important for maintaining pharmaceutical equivalence?
API stability affects pharmaceutical equivalence because degradation or changes in the active ingredient compromise the drug's potency and therapeutic effectiveness. Stability influences how the drug performs throughout its shelf life, making it essential that generic products maintain stability profiles equivalent to the innovator drug.